Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome.
Li H, Wang L, Wu Y, Su L, Zhao H, Zhang Y, Wang Z, Huang D, Huang Z, Wu X, Li X, Ye F, Yu F, Liu H, Wang JW, Cong J, Sun W, Chen HR, Wang J, Han B.
Li H, et al. Among authors: wang jw, wang l, wang z, wang j.
Acta Haematol. 2017;138(3):168-174. doi: 10.1159/000479485. Epub 2017 Oct 19.
Acta Haematol. 2017.
PMID: 29045939